Nemaura Medical to Present at the Bernstein 2ND Annual CGM Disruptors Conference

Rhea-AI Summary

Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will deliver a corporate overview at the Bernstein 2nd Annual CGM Disruptors Conference on November 18, 2022, at 10:30 AM ET. The company specializes in non-invasive wearable diagnostic devices, including the sugarBEAT® continuous glucose monitor, which is CE-mark approved and aimed at helping diabetes management. Nemaura is actively working on its Premarket Approval Application for sugarBEAT® with the U.S. FDA and has launched proBEAT™ in the U.S. as part of its BEAT®diabetes program.

Loughborough, England, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the Bernstein 2^nd Annual CGM Disruptors Conference which is being held virtually on November 18, 2022.

Event:	Bernstein 2ND Annual CGM Disruptors Conference
Presentation Date:	November 18, 2022
Time:	10:30am ET

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham (Media)
CORE IR
917-885-7378
julesa@coreir.com

Bret Shapiro (Investors)
Senior Managing Partner
CORE IR
(561) 479.8566
brets@coreir.com

FAQ

What is Nemaura Medical presenting at the Bernstein Conference?

Nemaura Medical will present a corporate overview at the Bernstein 2nd Annual CGM Disruptors Conference on November 18, 2022.

When is the Bernstein 2nd Annual CGM Disruptors Conference?

The conference will be held virtually on November 18, 2022.

Who is presenting for Nemaura Medical at the conference?

CEO Dr. Faz Chowdhury will present the corporate overview.

What time will Nemaura Medical's presentation take place?

The presentation is scheduled for 10:30 AM ET.

What products does Nemaura Medical develop?

Nemaura Medical develops non-invasive wearable devices, including sugarBEAT® and proBEAT™.

What is the market potential for Nemaura Medical's products?

The global Type 2 diabetes market is expected to reach nearly $59 billion by 2025, with additional opportunities in the pre-diabetic and wearable health-tech sectors.